LPL Financial LLC Has $3.57 Million Stock Position in Exelixis, Inc. (NASDAQ:EXEL)

LPL Financial LLC lifted its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 26.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 107,212 shares of the biotechnology company's stock after buying an additional 22,370 shares during the quarter. LPL Financial LLC's holdings in Exelixis were worth $3,570,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Allspring Global Investments Holdings LLC lifted its holdings in Exelixis by 82.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company's stock worth $52,884,000 after acquiring an additional 704,786 shares during the last quarter. Globeflex Capital L P raised its position in shares of Exelixis by 203.8% during the 4th quarter. Globeflex Capital L P now owns 975,151 shares of the biotechnology company's stock worth $32,473,000 after purchasing an additional 654,200 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Exelixis in the 4th quarter worth approximately $17,046,000. Burney Co. acquired a new position in Exelixis during the 4th quarter valued at approximately $12,267,000. Finally, Los Angeles Capital Management LLC boosted its position in Exelixis by 20.4% during the 4th quarter. Los Angeles Capital Management LLC now owns 2,156,996 shares of the biotechnology company's stock valued at $71,828,000 after purchasing an additional 366,141 shares during the period. 85.27% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on EXEL. Truist Financial raised their target price on Exelixis from $42.00 to $43.00 and gave the company a "buy" rating in a research note on Monday, January 27th. Guggenheim reiterated a "buy" rating and issued a $42.00 price objective on shares of Exelixis in a research report on Wednesday, February 12th. UBS Group upped their target price on shares of Exelixis from $30.00 to $34.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. Stifel Nicolaus lifted their target price on Exelixis from $30.00 to $36.00 and gave the company a "hold" rating in a research note on Wednesday, February 12th. Finally, Stephens restated an "equal weight" rating and set a $29.00 price objective on shares of Exelixis in a research note on Wednesday, February 12th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $37.59.

Remove Ads

Insider Activity

In other Exelixis news, Director Mary C. Beckerle sold 12,210 shares of the company's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the transaction, the director now owns 30,406 shares in the company, valued at approximately $1,060,561.28. This represents a 28.65 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Patrick J. Haley sold 52,636 shares of the business's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the transaction, the executive vice president now owns 303,310 shares in the company, valued at approximately $11,216,403.80. This represents a 14.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 140,343 shares of company stock worth $5,177,234 in the last 90 days. Company insiders own 2.85% of the company's stock.

Exelixis Stock Performance

Shares of NASDAQ:EXEL traded up $0.64 during mid-day trading on Tuesday, hitting $36.38. The stock had a trading volume of 1,125,395 shares, compared to its average volume of 2,170,104. The company's 50 day moving average is $36.21 and its 200-day moving average is $34.08. Exelixis, Inc. has a 12-month low of $20.14 and a 12-month high of $40.02. The company has a market cap of $10.18 billion, a PE ratio of 20.55, a P/E/G ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, equities research analysts predict that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.